Andere talen OncoZenge AB

Aandelen

ONCOZ

SE0015504097

Beurs gesloten - Nasdaq Stockholm Andere beurzen 17:02:19 03-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
3,84 ^SEK	-1,41%		-1,29%	+24,27%

08/04	Oncozenge AB (Publ) benoemt Paolo Bossi tot lid van de Raad van Advies	CI
04/04	OncoZenge kondigt positieve stabiliteitsgegevens voor BupiZenge aan	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

OncoZenge Appoints Anna Asplind as Phase 3 Program Manager	26/04
OncoZenge Releases Paper on BupiZenge™ Addressing Unmet Medical Needs	25/04
OncoZenge Appoints Åsa Nilsson as Clinical Research Manager	09/04
OncoZenge Announces Dr. Paolo Bossi as New Member of the Advisory Board	08/04
Oncozenge AB Appoints Paolo Bossi as Member of the Advisory Board	08/04
OncoZenge Announces Read-out of Positive Stability Data for BupiZenge™	04/04
OncoZenge Announces Read-Out of Positive Stability Data for BupiZenge	04/04
Oncozenge Explores Strategic Options for Bupizeng in China	11/03
OncoZenge Explores Strategic Options for BupiZenge™ in China	11/03
OncoZenge AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	15/02
OncoZenge Seeks to Expand Patent Protection for Oral Lozenge Product BupiZenge	07/02
OncoZenge Files Patent Application for Strengthened IP Protection for BupiZenge™	07/02
OncoZenge AB Files Patent Application for Strengthened IP Protection for BupiZenge	07/02
OncoZenge Seeks Priority Medicines Status for Oral Pain Treatment in Europe	02/01
OncoZenge submits application for PRIME status in the EU	02/01
OncoZenge Announces Advisory Board with Dr Stephen Sonis and Dr Pooja Nandwani Patel	13/12
Oncozenge Announces Formation of Advisory Board with Stephen Sonis and Pooja Nandwani Patel	13/12
Ensysce Biosciences Discusses TAAP and MPAR Applications and OncoZenge Partnership with the Stock Day Podcast	12/12
Ensysce Biosciences and OncoZenge Announce Letter of Intent for the Co-development of BupiZenge™ in the United States	28/11
Ensysce Biosciences and OncoZenge Announce Letter of Intent for the Co-Development of BupiZenge in the United States	28/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen OncoZenge AB

Aandelen

ONCOZ

SE0015504097

Andere talen

Filters